Leveraging Imaging Approaches to Define the Dynamics of SIV/HIV During & After ART & Adapting this Approach to Study SARS-CoV-2

Thomas J. Hope, PhD
Professor, Departments of Cell and Molecular Biology, Obstetrics and Gynecology, and Biomedical Engineering, Feinberg School of Medicine, Northwestern University, Chicago, IL



VIDEOTop of page

PRN no longer offers CME or ABIM MOC.Top of page

About the Presenter:Top of page

Thomas J. Hope, PH.D., Professor in the Department of Cell and Developmental Biology and Obstetrics and Gynecology in the Feinberg School of Medicine and in Biomedical Engineering in the McCormick School of Engineering and Applied Sciences at Northwestern University. Dr. Hope received his Ph.D. from the University of California, Berkeley, Department of Immunology, where he studied Molecular Immunology under Dr. H. Sakano. He completed his postdoctoral training at the University of California, San Francisco where he studied the HIV Rev protein. Dr. Hope’s laboratory has been a pioneer the use of cell biology approaches to study HIV providing images and movies of HIV interacting with cells and tissues. For the past 25 years, his research has focused on HIV Cellular Virology. More recently, this focus has expanded to HIV related mucosal immunology, HIV transmission, and HIV prevention science. His work has been published over the past three decades in respected journals such as Science, PNAS, The Journal of Cell Biology, Cell Host and Microbes, Journal of Virology, and PLoS Pathogens. Dr. Hope is also the Editor-in-Chief of AIDS Research and Human Retroviruses and a Section Editor for PLoS Pathogens. Dr. Hope is a widely respected speaker and gives talks about his innovative work on AIDS/HIV at many institutions and conferences, nationally and internationally.

Learning Objectives: Top of page

At the completion of this educational session, learners will:

  • Be aware of the different imaging modalities and how they are combined in multiscale imaging to elucidate the impact of anatomy and physiology on viral acquisition, pathogenesis, and treatment.
  • Know insights into the unique aspects of SIV rebound during the eclipse phase after stopping ART.
  • Understand progress in the development of antibody-derived probes to allow detection of SARS-CoV-2 infected cell in vivo.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

You must be logged in to post a comment. Login | Register